ANSTO: Landmark Achievement Opens Pathway for Treatment of Drug-Resistant TB

30 April 2026

Australia’s Nuclear Science and Technology Organisation (ANSTO) news release

Research revealed a hidden mechanism that activates a key enzyme, ICL2, in Mycobacterium tuberculosis, opening a new target pathway for treating drug-resistant TB.

Read the full news release here.

Source: ANSTO